Mitsubishi UFJ Asset Management Co. Ltd. Has $8.20 Million Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Key Points

• Mitsubishi UFJ Asset Management Co. Ltd. has reduced its holdings in Charles River Laboratories International by 32.6%, owning approximately 54,457 shares valued at about $8.2 million.
• Multiple analysts have upgraded their ratings on the stock, including Citigroup which raised its price target from $150 to $200, while the consensus price target stands at $175.69.
• Charles River Laboratories reported $3.12 earnings per share for the last quarter, exceeding expectations of $2.50, along with revenues of $1.03 billion against estimates of $983.76 million.

Mitsubishi UFJ Asset Management Co. Ltd. decreased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 32.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 54,457 shares of the medical research company's stock after selling 26,287 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.11% of Charles River Laboratories International worth $8,197,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the business. Two Sigma Securities LLC boosted its position in shares of Charles River Laboratories International by 4.3% during the 4th quarter. Two Sigma Securities LLC now owns 1,981 shares of the medical research company's stock valued at $366,000 after purchasing an additional 81 shares in the last quarter. Wahed Invest LLC boosted its position in shares of Charles River Laboratories International by 6.5% during the 4th quarter. Wahed Invest LLC now owns 1,321 shares of the medical research company's stock valued at $244,000 after purchasing an additional 81 shares in the last quarter. Teachers Retirement System of The State of Kentucky boosted its position in shares of Charles River Laboratories International by 2.7% during the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 3,916 shares of the medical research company's stock valued at $589,000 after purchasing an additional 102 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Charles River Laboratories International by 2.6% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,131 shares of the medical research company's stock valued at $763,000 after purchasing an additional 105 shares in the last quarter. Finally, Veracity Capital LLC boosted its holdings in shares of Charles River Laboratories International by 3.4% in the first quarter. Veracity Capital LLC now owns 3,298 shares of the medical research company's stock worth $496,000 after buying an additional 107 shares during the period. Institutional investors own 98.91% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on CRL. TD Cowen upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 target price for the company in a report on Wednesday, May 14th. Cowen raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating in a research report on Wednesday, May 14th. Barclays lifted their price target on shares of Charles River Laboratories International from $155.00 to $165.00 and gave the stock an "equal weight" rating in a research note on Thursday, August 7th. Wall Street Zen upgraded shares of Charles River Laboratories International from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 9th. Finally, JPMorgan Chase & Co. upped their price target on shares of Charles River Laboratories International from $145.00 to $160.00 and gave the stock a "neutral" rating in a research report on Thursday, August 7th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $175.69.

Charles River Laboratories International Stock Up 0.6%

NYSE:CRL traded up $0.86 during trading hours on Friday, reaching $156.66. 1,038,291 shares of the stock were exchanged, compared to its average volume of 1,079,568. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $230.02. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.36 and a quick ratio of 1.10. The firm has a 50 day moving average of $156.87 and a 200 day moving average of $148.95. The stock has a market cap of $7.71 billion, a PE ratio of -117.79, a PEG ratio of 4.97 and a beta of 1.48.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share for the quarter, topping analysts' consensus estimates of $2.50 by $0.62. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%. The firm had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $983.76 million. During the same quarter in the prior year, the firm posted $2.80 EPS. The business's revenue was up .6% on a year-over-year basis. On average, equities analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Insider Activity at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 400 shares of the stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $150.04, for a total value of $60,016.00. Following the completion of the sale, the executive vice president owned 24,916 shares of the company's stock, valued at approximately $3,738,396.64. This represents a 1.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 1.30% of the company's stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).